BIOA · BioAge Labs, Inc.
$21.93
+1.05 (+5.00%)
At close · Jul 28
Market Cap
$928.17M
Shares
44.45M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$20.88
Open$21.96
Day$20.75–22.95
52W$4.11–25.96
Avg vol 30d615K
Short int2.5M · 5.5% float · 4.5d
Short vol60%
Last earningsApr 21, 2026
DataSep 2024–Jul 2026
Filing10-Q · May 8
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+29%
above
Price vs 50-day avg
+4%
above
RSI (14)
44
neutral
MACD trend
Negative
52-week position
77%
mid-range
Momentum
relative strength
1-month return
−8%
trailing
6-month return
+10%
trailing
YTD return
+58%
this year
Relative strength
+4%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $20 › 200d $16 — 50d above 200d
Institutional flow
Distributing
18 of 145 funds reported for Jun 30 · net -151.5K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.51% of float · ▼ -34.5% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
145 holders — near 1-yr high, broad support
Squeeze score
53
elevated · 0–100
Fundamentals
EPS growth
+66%
Y/Y
Free cash flow
$-82.3M
Balance sheet
$186.2M
net cash
Quant / Vol
risk profile
Volatility
85%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
7.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+29%
Bullish
Price vs 50-day avg
+4%
Bullish
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
77%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $20 › 200d $16 — 50d above 200d
Institutional flow
Distributing
18 of 145 funds reported for Jun 30 · net -151.5K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.51% of float · ▼ -34.5% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
145 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $4
Now $21 · 77%
52-wk high $26
vs 200-day avg +29%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BIOA
this stock
BioAge Labs, Inc.
|
$928.17M | +57.8% | — | — | 5.5% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$56.03B | +12.4% | — | — | 0.1% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$51.90B | — | — | — | 0.0% |
|
GALDY
Galderma Group AG/ADR
|
$50.49B | +4.5% | — | — | 0.0% |
|
HLN
Haleon plc
|
$45.23B | +1.6% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BIOA | -8.5% | -7.7% | +10.0% | -14.8% | +57.8% |
| SPY | -0.4% | +1.4% | +6.3% | -1.0% | +8.4% |
| vs SPY | -8.1% | -9.1% | +3.7% | -13.8% | +49.4% |
Key facts
CIK
1709941
CUSIP
09077V100
13F (30d)
17 filings
17 filers
Visit website
Investor relations